- Human Coagulation
- Bovine Coagulation
- Animal Coagulation
- Substrates
- Venom Proteins
- Antibodies
- Plasmas
- Connective Tissue Proteins
- Protein Stabilizer
- r2 Diagnostics
- DSM Pentapharm
Quick Contact
Ecarin
Size: 3 x 50 EU
For the determination of Prothrombin and Hirudin. Specifically activates prothrombin via meizothrombin.
Ecarin is a metalloprotease isolated from the venom of the saw-scaled viper (Echis carinatus) that activates prothrombin. Ecarin does not affect other clotting factors. The action of ecarin on prothrombin is independent of calcium, phospholipids and factor V. Moreover, Ecarin, in contrast to factor Xa, activates the acarboxy form of prothrombin present in plasma of patients undergoing oral anticoagulant therapy with vitamin K antagonists.
Determination of prothrombin levels in patients undergoing anticoagulant therapy. Based on the interaction of hirudin with meizothrombin a simple ecarin clotting test for the monitoring of hirudin levels has been developed (Nowak and Bucha, 1993). Due to its action on acarboxy prothrombin, ecarin can be used for the determination of acarboxy prothrombin in the supernatent of barium sulfate treated patient plasma where normal carboxylated prothrombin has been removed by adsorption. Ecarin can be used for the detection of low prothrombin concentrations in plasma fractions for quality- and in-process control purposes. Ecarin, used in conjunction with the phospholipid- and calcium ion-dependent prothrombin activator Textarin from Pseudonaja textilis venom, forms a highly sensitive and specific test system for lupus anticoagulant (Triplett et al., 1993).
Packsize contains 3 x 50 EU vials
Molecular Weight: approx. 55,000 - 60,000
References
1. Triplett DA, Stocker KF, Unger GA, Barna LK. The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 1993; 70: 925-31.
2. Nowak G. Monitoring of the action of antithrombin agents by ecarin clotting time. In: New anticoagulants for the cardiovascular patient. Pifarré R, ed. Philadelphia: Hanley & Belfus 1997; 539-48.
3. Pötzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Müller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass assessment of the whole blood ecarin clotting time. Thromb Haemost 1997; 77: 920-25.
4. Nowak G. Clinical Monitoring of Hirudin and Direct Thrombin Inhibitors. Sem. Thromb Haemost 2001; 27: 537-41.
Related Products
Bovine Prothrombin (Factor II)Hirudin (HV-1)
Human Prothrombin (Factor II)
Batroxobin Maranhao 1000BU vial
Protac
Ecarin
Convulxin
RVV-Factor V Activator
RVV Factor X Activator
RVV-Factor X Activator